Clinical Trial

A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

Study acronym: QUAD
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated March 23, 2026 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
This study will evaluate the feasibility of combining four of the most active agents available for the treatment of multiple myeloma. Further the investigators will attempt to assess the activity of this combination.
Protocol Amendment History 19 amendments
This ClinicalTrials.gov record has been amended 19 times since 2011-02-16; most recent amendment 2026-03-20.
Status change: Recruiting → Active, Not Recruiting 2018-08-06
Status change: Not Yet Recruiting → Recruiting 2011-10-13
Trial Details
NCT Number NCT01297764
Lead Sponsor Hackensack Meridian Health
Conditions Multiple Myeloma
Enrollment 17 participants
Start Date 2011-04
Primary Completion 2026-07 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2026-03-23